Abstract
Diabetic retinopathy (DR) is a major diabetes complication and the leading cause for vision loss and blindness in the adult human population. Diabetes, being an endocrinological disorder dysregulates a number of hormonal systems including the renin angiotensin system (RAS), which thereby may damage both vascular and neuronal cells in the retina. Angiotensin II (Ang II), an active component of the RAS is increased in diabetic retina, and may play a significant role in neurovascular damage leading to the progression of DR. In this review article, we highlight the role of Ang II in the pathogenesis of retinal damage in diabetes and discuss a newly identified mechanism involving tissue chymase and angiotensin-(1-12) [Ang-(1-12)] pathways. We also discuss the therapeutic effects of potential RAS inhibitors targeting blockade of cellular Ang II formation to prevent/ protect the retinal damage. Thus, a better understanding of Ang II formation pathways in the diabetic retina will elucidate early molecular mechanism of vision loss. These concepts may provide a novel strategy for preventing and/or treating diabetic retinopathy, a leading cause of blindness worldwide.
Keywords: Angiotensin II, chymase, diabetic retinopathy, neurodegeneration, oxidative stress, renin-angiotensin system, retina.
Current Medicinal Chemistry
Title:Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy
Volume: 24 Issue: 28
Author(s): Mohammad Shamsul Ola*, Abdullah S. Alhomida, Carlos M. Ferrario and Sarfaraz Ahmad*
Affiliation:
- Department of Biochemistry, College of Science, King Saud, University, Riyadh 11451,Saudi Arabia
- Department of General Surgery, Wake Forest University Health Science, Winston-Salem, NC 27157,United States
Keywords: Angiotensin II, chymase, diabetic retinopathy, neurodegeneration, oxidative stress, renin-angiotensin system, retina.
Abstract: Diabetic retinopathy (DR) is a major diabetes complication and the leading cause for vision loss and blindness in the adult human population. Diabetes, being an endocrinological disorder dysregulates a number of hormonal systems including the renin angiotensin system (RAS), which thereby may damage both vascular and neuronal cells in the retina. Angiotensin II (Ang II), an active component of the RAS is increased in diabetic retina, and may play a significant role in neurovascular damage leading to the progression of DR. In this review article, we highlight the role of Ang II in the pathogenesis of retinal damage in diabetes and discuss a newly identified mechanism involving tissue chymase and angiotensin-(1-12) [Ang-(1-12)] pathways. We also discuss the therapeutic effects of potential RAS inhibitors targeting blockade of cellular Ang II formation to prevent/ protect the retinal damage. Thus, a better understanding of Ang II formation pathways in the diabetic retina will elucidate early molecular mechanism of vision loss. These concepts may provide a novel strategy for preventing and/or treating diabetic retinopathy, a leading cause of blindness worldwide.
Export Options
About this article
Cite this article as:
Ola Shamsul Mohammad*, Alhomida S. Abdullah , Ferrario M. Carlos and Ahmad Sarfaraz *, Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy, Current Medicinal Chemistry 2017; 24 (28) . https://dx.doi.org/10.2174/0929867324666170407141955
DOI https://dx.doi.org/10.2174/0929867324666170407141955 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Subject Index To Volume 1
Recent Patents on Cardiovascular Drug Discovery Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia
Current Neurovascular Research Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy
Current Medicinal Chemistry Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Synthesis and Antimicrobial Activity Evaluation of the Pyrrole-Derived Heterocycles Bearing Two Functionalities
Current Organic Synthesis P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways
Current Neurovascular Research Calcium Homeostasis Following Traumatic Neuronal Injury
Current Neurovascular Research Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science Hypothalamic and Neuroendocrine Changes in Huntingtons Disease
Current Drug Targets The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews